SCHEMBL14914554

SCHEMBL14914554

N=C(S)NCCc1ccc(CCNC(=N)S)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ST14 Q9Y5Y6 2/20 0.47
KDM4E B2RXH2 1/20 0.44
F13A1 P00488 1/20 0.44
SMN1; SMN2 Q16637 3/20 0.43
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
IDO1 P14902 1/20 0.42
ALDH1A1 P00352 1/20 0.40
TMEM97 Q5BJF2 1/20 0.40
SIGMAR1 Q99720 1/20 0.40
CA12 O43570 2/20 0.39
CA2 P00918 2/20 0.39
CA9 Q16790 2/20 0.39
CA1 P00915 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C19 P33261 1/20 0.39
CNR1 P21554 1/20 0.39
EPHX1 P07099 1/20 0.38
LMNA P02545 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10326271 0.83 MTNR1A (0.45) SMN1; SMN2NPC1RAB9AALDH1A1CA12
SCHEMBL7865714 0.76 KDM4E (0.53) ST14KDM4EF13A1SMN1; SMN2NPC1
SCHEMBL8620792 0.75 HRH4 (0.58)
SCHEMBL14467311 0.74 HDAC1 (0.48) IDO1CNR1TAAR1
SCHEMBL6682640 0.74 ST14 (0.50) ST14KDM4EF13A1SMN1; SMN2NPC1
SCHEMBL9196642 0.73 NOS1 (0.56) NPC1RAB9AIDO1CYP2D6
SCHEMBL12401907 0.71 ST14 (0.51) ST14KDM4EF13A1SMN1; SMN2NPC1
SCHEMBL20144285 0.70 KDM4E (0.67) KDM4EF13A1SMN1; SMN2NPC1RAB9A
SCHEMBL20911609 0.70 NPC1 (0.53) KDM4EF13A1SMN1; SMN2NPC1RAB9A
SCHEMBL6679010 0.70 ST14 (0.50) ST14KDM4EF13A1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12023303-B2 System for determining accuracy of serially-connected drug modules in a combinatorial drug delivery device using voltage BRISTOL-MYERS SQUIBB COMPANY (US) 2024-07-02 US disclosed
EP-4344695-A2 COMBINATORIAL DRUG DELIVERY DEVICE Bristol-Myers Squibb Company (US) 2024-04-03 EP disclosed
US-11944588-B2 Devices and systems for delivery of combination therapies BRISTOL-MYERS SQUIBB COMPANY (US) 2024-04-02 US disclosed
EP-3790525-B1 COMBINATORIAL DRUG DELIVERY DEVICE BRISTOL MYERS SQUIBB CO (US) 2024-03-20 EP disclosed
EP-4054511-B1 SYSTEM FOR DETERMINING ACCURACY OF SERIALLY-CONNECTED DRUG MODULES IN A COMBINATORIAL DRUG DELIVERY DEVICE USING VOLTAGE BRISTOL MYERS SQUIBB CO (US) 2024-03-13 EP disclosed
EP-4331556-A2 DEVICES AND SYSTEMS FOR DELIVERY OF COMBINATION THERAPIES Bristol-Myers Squibb Company (US) 2024-03-06 EP disclosed
EP-3790524-B1 DEVICES AND SYSTEMS FOR DELIVERY OF COMBINATION THERAPIES BRISTOL MYERS SQUIBB CO (US) 2024-02-28 EP disclosed
US-20240058529-A1 SYSTEM FOR VERIFYING ACCURACY OF SERIALLY-CONNECTED DRUG MODULES IN A COMBINATORIAL DRUG DELIVERY DEVICE BRISTOL MYERS SQUIBB CO (US) 2024-02-22 US disclosed
US-20240009081-A1 COMBINATORIAL DRUG DELIVERY DEVICE BRISTOL MYERS SQUIBB CO (US) 2024-01-11 US disclosed
US-11844927-B2 System for verifying accuracy of serially-connected drug modules in a combinatorial drug delivery device BRISTOL-MYERS SQUIBB COMPANY (US) 2023-12-19 US disclosed
EP-4245375-A2 COMPOSITIONS COMPRISING A COMBINATION OF AN ANTI-LAG-3 ANTIBODY, A PD-1 PATHWAY INHIBITOR, AND AN IMMUNOTHERAPEUTIC AGENT Bristol-Myers Squibb Company (US) 2023-09-20 EP disclosed
US-20230111786-A1 COMPOSITIONS COMPRISING A COMBINATION OF AN ANTI-LAG-3 ANTIBODY, A PD-1 PATHWAY INHIBITOR, AND AN IMMUNOTHERAPEUTIC AGENT BRISTOL-MYERS SQUIBB COMPANY (US) 2023-04-13 US disclosed
US-20230044334-A1 COMBINATORIAL DRUG DELIVERY DEVICE BRISTOL MYERS SQUIBB CO (US) 2023-02-09 US disclosed
US-20220395631-A1 RADIALLY ADJUSTABLE MULTI-CARTRIDGE COMBINATORIAL DRUG DELIVERY DEVICE FOR SUBCUTANEOUS INJECTION BRISTOL MYERS SQUIBB CO (US) 2022-12-15 US disclosed
US-20220378656-A1 SYSTEM FOR DETERMINING ACCURACY OF SERIALLY-CONNECTED DRUG MODULES IN A COMBINATORIAL DRUG DELIVERY DEVICE USING VOLTAGE BRISTOL MYERS SQUIBB CO (US) 2022-12-01 US disclosed
US-20220023531-A1 DEVICES AND SYSTEMS FOR DELIVERY OF COMBINATION THERAPIES BRISTOL MYERS SQUIBB CO (US) 2022-01-27 US disclosed
US-20210340250-A1 COMPOSITIONS COMPRISING A COMBINATION OF AN ANTI-LAG-3 ANTIBODY, A PD-1 PATHWAY INHIBITOR, AND AN IMMUNOTHERAPEUTIC AGENT BRISTOL-MYERS SQUIBB COMPANY (US) 2021-11-04 US disclosed
US-20210154097-A1 SERIALLY-CONNECTABLE DRUG MODULES FOR COMBINATORIAL DRUG DELIVERY DEVICE BRISTOL MYERS SQUIBB CO (US) 2021-05-27 US disclosed
US-20210145696-A1 COMBINATORIAL DRUG DELIVERY DEVICE BRISTOL MYERS SQUIBB CO (US) 2021-05-20 US disclosed
US-20130115322-A1 Therapeutic Compositions and Methods for Treating Cell Dysplasia Using Extracts From Raspberry and Strawberry THE OHIO STATE UNIVERSITY 2013-05-09 US disclosed